nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—CYP1A2—type 2 diabetes mellitus	0.0962	0.447	CbGaD
Imatinib—CYP3A4—type 2 diabetes mellitus	0.0637	0.296	CbGaD
Imatinib—ALB—type 2 diabetes mellitus	0.0555	0.258	CbGaD
Imatinib—SLC47A1—Metformin—type 2 diabetes mellitus	0.0233	0.0503	CbGbCtD
Imatinib—ORM1—Nateglinide—type 2 diabetes mellitus	0.0213	0.046	CbGbCtD
Imatinib—PTGS1—Pioglitazone—type 2 diabetes mellitus	0.0158	0.0342	CbGbCtD
Imatinib—PTGS1—Chlorpropamide—type 2 diabetes mellitus	0.0158	0.0342	CbGbCtD
Imatinib—PTGS1—Rosiglitazone—type 2 diabetes mellitus	0.0146	0.0316	CbGbCtD
Imatinib—ALB—Gliclazide—type 2 diabetes mellitus	0.0139	0.03	CbGbCtD
Imatinib—ALB—Repaglinide—type 2 diabetes mellitus	0.0131	0.0282	CbGbCtD
Imatinib—PTGS1—Nateglinide—type 2 diabetes mellitus	0.012	0.0259	CbGbCtD
Imatinib—PTGS1—Irbesartan—type 2 diabetes mellitus	0.0115	0.0249	CbGbCtD
Imatinib—ALB—Rosiglitazone—type 2 diabetes mellitus	0.0109	0.0236	CbGbCtD
Imatinib—ALB—Valsartan—type 2 diabetes mellitus	0.00963	0.0208	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Nateglinide—type 2 diabetes mellitus	0.00959	0.0207	CbGbCtD
Imatinib—CYP3A7—Nateglinide—type 2 diabetes mellitus	0.00959	0.0207	CbGbCtD
Imatinib—ABCB1—Linagliptin—type 2 diabetes mellitus	0.00959	0.0207	CbGbCtD
Imatinib—CYP2C19—Gliclazide—type 2 diabetes mellitus	0.00901	0.0195	CbGbCtD
Imatinib—ALB—Nateglinide—type 2 diabetes mellitus	0.00895	0.0194	CbGbCtD
Imatinib—CYP2C9—Glimepiride—type 2 diabetes mellitus	0.00881	0.019	CbGbCtD
Imatinib—ABCG2—Glyburide—type 2 diabetes mellitus	0.00877	0.019	CbGbCtD
Imatinib—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.00855	0.0185	CbGbCtD
Imatinib—CYP2C9—Glipizide—type 2 diabetes mellitus	0.00805	0.0174	CbGbCtD
Imatinib—CYP2C19—Pioglitazone—type 2 diabetes mellitus	0.00766	0.0166	CbGbCtD
Imatinib—CYP2C19—Chlorpropamide—type 2 diabetes mellitus	0.00766	0.0166	CbGbCtD
Imatinib—CYP2C9—Gliclazide—type 2 diabetes mellitus	0.00749	0.0162	CbGbCtD
Imatinib—SLC22A2—Metformin—type 2 diabetes mellitus	0.0072	0.0156	CbGbCtD
Imatinib—CYP3A5—Nateglinide—type 2 diabetes mellitus	0.0072	0.0156	CbGbCtD
Imatinib—CYP2C19—Rosiglitazone—type 2 diabetes mellitus	0.00707	0.0153	CbGbCtD
Imatinib—CYP2C19—Tolbutamide—type 2 diabetes mellitus	0.00683	0.0148	CbGbCtD
Imatinib—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.00652	0.0141	CbGbCtD
Imatinib—CYP2C9—Pioglitazone—type 2 diabetes mellitus	0.00637	0.0138	CbGbCtD
Imatinib—CYP2C9—Chlorpropamide—type 2 diabetes mellitus	0.00637	0.0138	CbGbCtD
Imatinib—SLC22A1—Metformin—type 2 diabetes mellitus	0.00626	0.0135	CbGbCtD
Imatinib—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.00618	0.0134	CbGbCtD
Imatinib—ALB—Glyburide—type 2 diabetes mellitus	0.00605	0.0131	CbGbCtD
Imatinib—CYP2C9—Rosiglitazone—type 2 diabetes mellitus	0.00588	0.0127	CbGbCtD
Imatinib—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.00582	0.0126	CbGbCtD
Imatinib—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00575	0.0124	CbGbCtD
Imatinib—CYP2C9—Tolbutamide—type 2 diabetes mellitus	0.00568	0.0123	CbGbCtD
Imatinib—ALB—Losartan—type 2 diabetes mellitus	0.00553	0.012	CbGbCtD
Imatinib—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.00537	0.0116	CbGbCtD
Imatinib—CYP2C9—Valsartan—type 2 diabetes mellitus	0.00519	0.0112	CbGbCtD
Imatinib—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.00513	0.0111	CbGbCtD
Imatinib—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00512	0.0111	CbGbCtD
Imatinib—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.00486	0.0105	CbGbCtD
Imatinib—CYP2C9—Nateglinide—type 2 diabetes mellitus	0.00483	0.0104	CbGbCtD
Imatinib—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00468	0.0101	CbGbCtD
Imatinib—CYP2C9—Irbesartan—type 2 diabetes mellitus	0.00463	0.01	CbGbCtD
Imatinib—CYP3A5—Losartan—type 2 diabetes mellitus	0.00445	0.00961	CbGbCtD
Imatinib—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00441	0.00954	CbGbCtD
Imatinib—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00425	0.00918	CbGbCtD
Imatinib—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.00423	0.00915	CbGbCtD
Imatinib—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00409	0.00885	CbGbCtD
Imatinib—CYP2C19—Glyburide—type 2 diabetes mellitus	0.00392	0.00848	CbGbCtD
Imatinib—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0037	0.008	CbGbCtD
Imatinib—CYP2C19—Losartan—type 2 diabetes mellitus	0.00359	0.00775	CbGbCtD
Imatinib—CYP1A2—Losartan—type 2 diabetes mellitus	0.00331	0.00715	CbGbCtD
Imatinib—CYP2C9—Glyburide—type 2 diabetes mellitus	0.00326	0.00705	CbGbCtD
Imatinib—ABCB1—Glyburide—type 2 diabetes mellitus	0.00316	0.00684	CbGbCtD
Imatinib—CYP2C9—Losartan—type 2 diabetes mellitus	0.00298	0.00645	CbGbCtD
Imatinib—ABCB1—Losartan—type 2 diabetes mellitus	0.00289	0.00626	CbGbCtD
Imatinib—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00281	0.00607	CbGbCtD
Imatinib—PDGFRA—penis—type 2 diabetes mellitus	0.0027	0.0554	CbGeAlD
Imatinib—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00269	0.00582	CbGbCtD
Imatinib—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00269	0.00582	CbGbCtD
Imatinib—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00254	0.0055	CbGbCtD
Imatinib—CYP3A4—Glyburide—type 2 diabetes mellitus	0.0019	0.0041	CbGbCtD
Imatinib—CYP3A4—Losartan—type 2 diabetes mellitus	0.00173	0.00375	CbGbCtD
Imatinib—ABCA3—islet of Langerhans—type 2 diabetes mellitus	0.00144	0.0295	CbGeAlD
Imatinib—DDR1—islet of Langerhans—type 2 diabetes mellitus	0.00133	0.0272	CbGeAlD
Imatinib—Ponatinib—SRC—type 2 diabetes mellitus	0.00109	0.547	CrCbGaD
Imatinib—DDR1—nephron tubule—type 2 diabetes mellitus	0.00107	0.0219	CbGeAlD
Imatinib—ABCA3—cortex of kidney—type 2 diabetes mellitus	0.00099	0.0203	CbGeAlD
Imatinib—DDR1—pancreas—type 2 diabetes mellitus	0.000932	0.0191	CbGeAlD
Imatinib—ABCA3—adipose tissue—type 2 diabetes mellitus	0.000916	0.0188	CbGeAlD
Imatinib—DDR1—cortex of kidney—type 2 diabetes mellitus	0.000914	0.0188	CbGeAlD
Imatinib—CA1—nerve—type 2 diabetes mellitus	0.000905	0.0186	CbGeAlD
Imatinib—DDR1—adipose tissue—type 2 diabetes mellitus	0.000846	0.0174	CbGeAlD
Imatinib—KIT—endothelium—type 2 diabetes mellitus	0.000843	0.0173	CbGeAlD
Imatinib—PIP4K2C—islet of Langerhans—type 2 diabetes mellitus	0.000818	0.0168	CbGeAlD
Imatinib—CA9—islet of Langerhans—type 2 diabetes mellitus	0.000748	0.0154	CbGeAlD
Imatinib—PIP4K2C—retina—type 2 diabetes mellitus	0.0007	0.0144	CbGeAlD
Imatinib—PIP4K2C—nephron tubule—type 2 diabetes mellitus	0.000659	0.0135	CbGeAlD
Imatinib—CA7—kidney—type 2 diabetes mellitus	0.000603	0.0124	CbGeAlD
Imatinib—NQO2—islet of Langerhans—type 2 diabetes mellitus	0.000601	0.0123	CbGeAlD
Imatinib—DDR1—liver—type 2 diabetes mellitus	0.000593	0.0122	CbGeAlD
Imatinib—PIP4K2C—pancreas—type 2 diabetes mellitus	0.000575	0.0118	CbGeAlD
Imatinib—CA3—cardiovascular system—type 2 diabetes mellitus	0.000565	0.0116	CbGeAlD
Imatinib—PIP4K2C—cortex of kidney—type 2 diabetes mellitus	0.000564	0.0116	CbGeAlD
Imatinib—ABL2—adipose tissue—type 2 diabetes mellitus	0.000552	0.0113	CbGeAlD
Imatinib—PIP4K2C—adipose tissue—type 2 diabetes mellitus	0.000522	0.0107	CbGeAlD
Imatinib—CA3—adipose tissue—type 2 diabetes mellitus	0.000498	0.0102	CbGeAlD
Imatinib—NQO2—nephron tubule—type 2 diabetes mellitus	0.000484	0.00994	CbGeAlD
Imatinib—CYP3A7-CYP3A51P—nephron tubule—type 2 diabetes mellitus	0.000475	0.00976	CbGeAlD
Imatinib—PDGFRB—islet of Langerhans—type 2 diabetes mellitus	0.000468	0.00962	CbGeAlD
Imatinib—LCK—adipose tissue—type 2 diabetes mellitus	0.000463	0.00952	CbGeAlD
Imatinib—SLC22A2—nephron tubule—type 2 diabetes mellitus	0.000459	0.00942	CbGeAlD
Imatinib—PTGS1—artery—type 2 diabetes mellitus	0.000457	0.00938	CbGeAlD
Imatinib—Meclizine—CYP1A2—type 2 diabetes mellitus	0.000437	0.22	CrCbGaD
Imatinib—PDGFRA—cardiovascular system—type 2 diabetes mellitus	0.000434	0.00891	CbGeAlD
Imatinib—NQO2—kidney—type 2 diabetes mellitus	0.000425	0.00874	CbGeAlD
Imatinib—NQO2—pancreas—type 2 diabetes mellitus	0.000423	0.00868	CbGeAlD
Imatinib—ABL1—islet of Langerhans—type 2 diabetes mellitus	0.000417	0.00857	CbGeAlD
Imatinib—NQO2—cortex of kidney—type 2 diabetes mellitus	0.000414	0.00851	CbGeAlD
Imatinib—CYP3A7-CYP3A51P—cortex of kidney—type 2 diabetes mellitus	0.000407	0.00835	CbGeAlD
Imatinib—SLC22A2—kidney—type 2 diabetes mellitus	0.000403	0.00828	CbGeAlD
Imatinib—SLC22A2—cortex of kidney—type 2 diabetes mellitus	0.000392	0.00806	CbGeAlD
Imatinib—CA12—kidney—type 2 diabetes mellitus	0.000392	0.00804	CbGeAlD
Imatinib—SLC47A1—nephron tubule—type 2 diabetes mellitus	0.000388	0.00797	CbGeAlD
Imatinib—ABL2—liver—type 2 diabetes mellitus	0.000387	0.00795	CbGeAlD
Imatinib—KIT—nephron tubule—type 2 diabetes mellitus	0.000386	0.00793	CbGeAlD
Imatinib—PTGS1—endothelium—type 2 diabetes mellitus	0.000386	0.00792	CbGeAlD
Imatinib—NQO2—adipose tissue—type 2 diabetes mellitus	0.000383	0.00787	CbGeAlD
Imatinib—PDGFRA—adipose tissue—type 2 diabetes mellitus	0.000382	0.00785	CbGeAlD
Imatinib—CSF1R—cardiovascular system—type 2 diabetes mellitus	0.000382	0.00784	CbGeAlD
Imatinib—PIP4K2C—liver—type 2 diabetes mellitus	0.000366	0.00752	CbGeAlD
Imatinib—ABL1—retina—type 2 diabetes mellitus	0.000357	0.00733	CbGeAlD
Imatinib—CA3—liver—type 2 diabetes mellitus	0.00035	0.00718	CbGeAlD
Imatinib—KIT—cardiovascular system—type 2 diabetes mellitus	0.000347	0.00712	CbGeAlD
Imatinib—SLC47A1—kidney—type 2 diabetes mellitus	0.000341	0.00701	CbGeAlD
Imatinib—KIT—kidney—type 2 diabetes mellitus	0.000339	0.00697	CbGeAlD
Imatinib—PDGFRB—cardiovascular system—type 2 diabetes mellitus	0.000339	0.00695	CbGeAlD
Imatinib—KIT—pancreas—type 2 diabetes mellitus	0.000337	0.00692	CbGeAlD
Imatinib—CSF1R—adipose tissue—type 2 diabetes mellitus	0.000337	0.00692	CbGeAlD
Imatinib—ABL1—nephron tubule—type 2 diabetes mellitus	0.000336	0.0069	CbGeAlD
Imatinib—SLC47A1—cortex of kidney—type 2 diabetes mellitus	0.000332	0.00682	CbGeAlD
Imatinib—PDGFRB—kidney—type 2 diabetes mellitus	0.000331	0.0068	CbGeAlD
Imatinib—KIT—cortex of kidney—type 2 diabetes mellitus	0.00033	0.00679	CbGeAlD
Imatinib—PDGFRB—pancreas—type 2 diabetes mellitus	0.000329	0.00676	CbGeAlD
Imatinib—LCK—liver—type 2 diabetes mellitus	0.000325	0.00667	CbGeAlD
Imatinib—PDGFRB—cortex of kidney—type 2 diabetes mellitus	0.000323	0.00663	CbGeAlD
Imatinib—CA14—liver—type 2 diabetes mellitus	0.000317	0.00652	CbGeAlD
Imatinib—CA1—cardiovascular system—type 2 diabetes mellitus	0.000317	0.00651	CbGeAlD
Imatinib—CYP3A7—liver—type 2 diabetes mellitus	0.00031	0.00638	CbGeAlD
Imatinib—CA1—kidney—type 2 diabetes mellitus	0.00031	0.00637	CbGeAlD
Imatinib—CA1—pancreas—type 2 diabetes mellitus	0.000308	0.00633	CbGeAlD
Imatinib—SLC47A1—adipose tissue—type 2 diabetes mellitus	0.000307	0.00632	CbGeAlD
Imatinib—KIT—adipose tissue—type 2 diabetes mellitus	0.000306	0.00628	CbGeAlD
Imatinib—ABL1—cardiovascular system—type 2 diabetes mellitus	0.000302	0.0062	CbGeAlD
Imatinib—PDGFRB—adipose tissue—type 2 diabetes mellitus	0.000299	0.00613	CbGeAlD
Imatinib—ABL1—kidney—type 2 diabetes mellitus	0.000295	0.00606	CbGeAlD
Imatinib—ABL1—pancreas—type 2 diabetes mellitus	0.000293	0.00602	CbGeAlD
Imatinib—ABL1—cortex of kidney—type 2 diabetes mellitus	0.000288	0.00591	CbGeAlD
Imatinib—SLC22A1—kidney—type 2 diabetes mellitus	0.000285	0.00585	CbGeAlD
Imatinib—CA2—islet of Langerhans—type 2 diabetes mellitus	0.000284	0.00584	CbGeAlD
Imatinib—CA1—adipose tissue—type 2 diabetes mellitus	0.00028	0.00574	CbGeAlD
Imatinib—NQO2—liver—type 2 diabetes mellitus	0.000269	0.00552	CbGeAlD
Imatinib—PDGFRA—liver—type 2 diabetes mellitus	0.000268	0.00551	CbGeAlD
Imatinib—Ponatinib—CYP3A4—type 2 diabetes mellitus	0.000267	0.134	CrCbGaD
Imatinib—ABL1—adipose tissue—type 2 diabetes mellitus	0.000266	0.00547	CbGeAlD
Imatinib—CYP3A7-CYP3A51P—liver—type 2 diabetes mellitus	0.000264	0.00542	CbGeAlD
Imatinib—SLC22A1—adipose tissue—type 2 diabetes mellitus	0.000257	0.00527	CbGeAlD
Imatinib—CYP3A5—islet of Langerhans—type 2 diabetes mellitus	0.000244	0.00502	CbGeAlD
Imatinib—CA2—retina—type 2 diabetes mellitus	0.000243	0.00499	CbGeAlD
Imatinib—CSF1R—liver—type 2 diabetes mellitus	0.000236	0.00485	CbGeAlD
Imatinib—CA2—nephron tubule—type 2 diabetes mellitus	0.000229	0.0047	CbGeAlD
Imatinib—SLC47A1—liver—type 2 diabetes mellitus	0.000216	0.00443	CbGeAlD
Imatinib—KIT—liver—type 2 diabetes mellitus	0.000214	0.0044	CbGeAlD
Imatinib—ABCG2—nephron tubule—type 2 diabetes mellitus	0.000212	0.00435	CbGeAlD
Imatinib—PDGFRB—liver—type 2 diabetes mellitus	0.000209	0.0043	CbGeAlD
Imatinib—CA2—cardiovascular system—type 2 diabetes mellitus	0.000205	0.00422	CbGeAlD
Imatinib—CA2—kidney—type 2 diabetes mellitus	0.000201	0.00413	CbGeAlD
Imatinib—CA2—pancreas—type 2 diabetes mellitus	0.0002	0.0041	CbGeAlD
Imatinib—Nilotinib—CYP3A4—type 2 diabetes mellitus	0.000197	0.0991	CrCbGaD
Imatinib—CYP3A5—nephron tubule—type 2 diabetes mellitus	0.000197	0.00404	CbGeAlD
Imatinib—ORM1—liver—type 2 diabetes mellitus	0.000196	0.00403	CbGeAlD
Imatinib—CA1—liver—type 2 diabetes mellitus	0.000196	0.00403	CbGeAlD
Imatinib—CA2—cortex of kidney—type 2 diabetes mellitus	0.000196	0.00402	CbGeAlD
Imatinib—ABL1—liver—type 2 diabetes mellitus	0.000187	0.00383	CbGeAlD
Imatinib—CA2—adipose tissue—type 2 diabetes mellitus	0.000181	0.00372	CbGeAlD
Imatinib—SLC22A1—liver—type 2 diabetes mellitus	0.00018	0.0037	CbGeAlD
Imatinib—CYP2C9—cardiovascular system—type 2 diabetes mellitus	0.000174	0.00357	CbGeAlD
Imatinib—CYP3A5—kidney—type 2 diabetes mellitus	0.000173	0.00355	CbGeAlD
Imatinib—ALB—liver—type 2 diabetes mellitus	0.000172	0.00354	CbGeAlD
Imatinib—CYP3A5—pancreas—type 2 diabetes mellitus	0.000172	0.00353	CbGeAlD
Imatinib—CYP3A5—cortex of kidney—type 2 diabetes mellitus	0.000168	0.00346	CbGeAlD
Imatinib—ABCG2—adipose tissue—type 2 diabetes mellitus	0.000168	0.00345	CbGeAlD
Imatinib—PTGS1—cardiovascular system—type 2 diabetes mellitus	0.000159	0.00326	CbGeAlD
Imatinib—CYP3A5—adipose tissue—type 2 diabetes mellitus	0.000156	0.0032	CbGeAlD
Imatinib—PTGS1—kidney—type 2 diabetes mellitus	0.000155	0.00319	CbGeAlD
Imatinib—PTGS1—adipose tissue—type 2 diabetes mellitus	0.00014	0.00287	CbGeAlD
Imatinib—CYP2C19—liver—type 2 diabetes mellitus	0.000139	0.00285	CbGeAlD
Imatinib—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.00013	0.00267	CbGeAlD
Imatinib—CYP3A4—kidney—type 2 diabetes mellitus	0.00013	0.00266	CbGeAlD
Imatinib—CYP2D6—kidney—type 2 diabetes mellitus	0.000128	0.00262	CbGeAlD
Imatinib—CA2—liver—type 2 diabetes mellitus	0.000127	0.00261	CbGeAlD
Imatinib—ABCG2—liver—type 2 diabetes mellitus	0.000118	0.00242	CbGeAlD
Imatinib—CYP1A2—liver—type 2 diabetes mellitus	0.000113	0.00233	CbGeAlD
Imatinib—ABCB1—retina—type 2 diabetes mellitus	0.000111	0.00228	CbGeAlD
Imatinib—CYP3A5—liver—type 2 diabetes mellitus	0.000109	0.00224	CbGeAlD
Imatinib—CYP2C9—liver—type 2 diabetes mellitus	0.000108	0.00221	CbGeAlD
Imatinib—ABCB1—nephron tubule—type 2 diabetes mellitus	0.000104	0.00215	CbGeAlD
Imatinib—ABCB1—cardiovascular system—type 2 diabetes mellitus	9.38e-05	0.00193	CbGeAlD
Imatinib—ABCB1—kidney—type 2 diabetes mellitus	9.18e-05	0.00189	CbGeAlD
Imatinib—ABCB1—pancreas—type 2 diabetes mellitus	9.12e-05	0.00187	CbGeAlD
Imatinib—ABCB1—cortex of kidney—type 2 diabetes mellitus	8.94e-05	0.00184	CbGeAlD
Imatinib—ABCB1—adipose tissue—type 2 diabetes mellitus	8.27e-05	0.0017	CbGeAlD
Imatinib—CYP3A4—liver—type 2 diabetes mellitus	8.2e-05	0.00168	CbGeAlD
Imatinib—CYP2D6—liver—type 2 diabetes mellitus	8.07e-05	0.00166	CbGeAlD
Imatinib—ABCB1—liver—type 2 diabetes mellitus	5.8e-05	0.00119	CbGeAlD
Imatinib—Hypersensitivity—Glyburide—type 2 diabetes mellitus	4.73e-05	0.000283	CcSEcCtD
Imatinib—Nervous system disorder—Metformin—type 2 diabetes mellitus	4.73e-05	0.000283	CcSEcCtD
Imatinib—Thrombocytopenia—Metformin—type 2 diabetes mellitus	4.73e-05	0.000283	CcSEcCtD
Imatinib—Dyspnoea—Valsartan—type 2 diabetes mellitus	4.73e-05	0.000283	CcSEcCtD
Imatinib—Vertigo—Losartan—type 2 diabetes mellitus	4.72e-05	0.000283	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	4.72e-05	0.000282	CcSEcCtD
Imatinib—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	4.72e-05	0.000282	CcSEcCtD
Imatinib—Somnolence—Valsartan—type 2 diabetes mellitus	4.71e-05	0.000282	CcSEcCtD
Imatinib—Syncope—Losartan—type 2 diabetes mellitus	4.71e-05	0.000282	CcSEcCtD
Imatinib—Paraesthesia—Orlistat—type 2 diabetes mellitus	4.7e-05	0.000282	CcSEcCtD
Imatinib—Leukopenia—Losartan—type 2 diabetes mellitus	4.7e-05	0.000281	CcSEcCtD
Imatinib—Discomfort—Irbesartan—type 2 diabetes mellitus	4.7e-05	0.000281	CcSEcCtD
Imatinib—Skin disorder—Metformin—type 2 diabetes mellitus	4.69e-05	0.000281	CcSEcCtD
Imatinib—Immune system disorder—Ramipril—type 2 diabetes mellitus	4.67e-05	0.00028	CcSEcCtD
Imatinib—Hyperhidrosis—Metformin—type 2 diabetes mellitus	4.67e-05	0.000279	CcSEcCtD
Imatinib—Dyspepsia—Valsartan—type 2 diabetes mellitus	4.67e-05	0.000279	CcSEcCtD
Imatinib—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	4.66e-05	0.000279	CcSEcCtD
Imatinib—Dizziness—Bromocriptine—type 2 diabetes mellitus	4.65e-05	0.000278	CcSEcCtD
Imatinib—Dry mouth—Irbesartan—type 2 diabetes mellitus	4.65e-05	0.000278	CcSEcCtD
Imatinib—Palpitations—Losartan—type 2 diabetes mellitus	4.64e-05	0.000278	CcSEcCtD
Imatinib—Nausea—Glimepiride—type 2 diabetes mellitus	4.63e-05	0.000277	CcSEcCtD
Imatinib—Arrhythmia—Ramipril—type 2 diabetes mellitus	4.62e-05	0.000277	CcSEcCtD
Imatinib—Loss of consciousness—Losartan—type 2 diabetes mellitus	4.62e-05	0.000276	CcSEcCtD
Imatinib—Nausea—Sitagliptin—type 2 diabetes mellitus	4.61e-05	0.000276	CcSEcCtD
Imatinib—Dyspepsia—Orlistat—type 2 diabetes mellitus	4.61e-05	0.000276	CcSEcCtD
Imatinib—Asthenia—Glyburide—type 2 diabetes mellitus	4.61e-05	0.000276	CcSEcCtD
Imatinib—Decreased appetite—Valsartan—type 2 diabetes mellitus	4.61e-05	0.000276	CcSEcCtD
Imatinib—Anorexia—Metformin—type 2 diabetes mellitus	4.6e-05	0.000275	CcSEcCtD
Imatinib—Cough—Losartan—type 2 diabetes mellitus	4.58e-05	0.000274	CcSEcCtD
Imatinib—Urticaria—Gliclazide—type 2 diabetes mellitus	4.58e-05	0.000274	CcSEcCtD
Imatinib—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	4.58e-05	0.000274	CcSEcCtD
Imatinib—Alopecia—Ramipril—type 2 diabetes mellitus	4.57e-05	0.000274	CcSEcCtD
Imatinib—Fatigue—Valsartan—type 2 diabetes mellitus	4.57e-05	0.000274	CcSEcCtD
Imatinib—Abdominal pain—Gliclazide—type 2 diabetes mellitus	4.56e-05	0.000273	CcSEcCtD
Imatinib—Body temperature increased—Gliclazide—type 2 diabetes mellitus	4.56e-05	0.000273	CcSEcCtD
Imatinib—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	4.56e-05	0.000273	CcSEcCtD
Imatinib—Oedema—Irbesartan—type 2 diabetes mellitus	4.56e-05	0.000273	CcSEcCtD
Imatinib—Decreased appetite—Orlistat—type 2 diabetes mellitus	4.55e-05	0.000273	CcSEcCtD
Imatinib—Pruritus—Glyburide—type 2 diabetes mellitus	4.55e-05	0.000272	CcSEcCtD
Imatinib—Mental disorder—Ramipril—type 2 diabetes mellitus	4.53e-05	0.000271	CcSEcCtD
Imatinib—Constipation—Valsartan—type 2 diabetes mellitus	4.53e-05	0.000271	CcSEcCtD
Imatinib—Infection—Irbesartan—type 2 diabetes mellitus	4.53e-05	0.000271	CcSEcCtD
Imatinib—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	4.52e-05	0.000271	CcSEcCtD
Imatinib—Fatigue—Orlistat—type 2 diabetes mellitus	4.52e-05	0.00027	CcSEcCtD
Imatinib—Hypotension—Metformin—type 2 diabetes mellitus	4.51e-05	0.00027	CcSEcCtD
Imatinib—Erythema—Ramipril—type 2 diabetes mellitus	4.5e-05	0.00027	CcSEcCtD
Imatinib—Malnutrition—Ramipril—type 2 diabetes mellitus	4.5e-05	0.00027	CcSEcCtD
Imatinib—Shock—Irbesartan—type 2 diabetes mellitus	4.48e-05	0.000268	CcSEcCtD
Imatinib—Pain—Orlistat—type 2 diabetes mellitus	4.48e-05	0.000268	CcSEcCtD
Imatinib—Arthralgia—Losartan—type 2 diabetes mellitus	4.47e-05	0.000268	CcSEcCtD
Imatinib—Chest pain—Losartan—type 2 diabetes mellitus	4.47e-05	0.000268	CcSEcCtD
Imatinib—Myalgia—Losartan—type 2 diabetes mellitus	4.47e-05	0.000268	CcSEcCtD
Imatinib—Vomiting—Bromocriptine—type 2 diabetes mellitus	4.47e-05	0.000268	CcSEcCtD
Imatinib—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	4.47e-05	0.000267	CcSEcCtD
Imatinib—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	4.46e-05	0.000267	CcSEcCtD
Imatinib—Anxiety—Losartan—type 2 diabetes mellitus	4.46e-05	0.000267	CcSEcCtD
Imatinib—Tachycardia—Irbesartan—type 2 diabetes mellitus	4.45e-05	0.000266	CcSEcCtD
Imatinib—Rash—Bromocriptine—type 2 diabetes mellitus	4.43e-05	0.000265	CcSEcCtD
Imatinib—Dermatitis—Bromocriptine—type 2 diabetes mellitus	4.43e-05	0.000265	CcSEcCtD
Imatinib—Skin disorder—Irbesartan—type 2 diabetes mellitus	4.42e-05	0.000265	CcSEcCtD
Imatinib—Discomfort—Losartan—type 2 diabetes mellitus	4.42e-05	0.000264	CcSEcCtD
Imatinib—Dysgeusia—Ramipril—type 2 diabetes mellitus	4.41e-05	0.000264	CcSEcCtD
Imatinib—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	4.4e-05	0.000264	CcSEcCtD
Imatinib—Headache—Bromocriptine—type 2 diabetes mellitus	4.4e-05	0.000264	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	4.4e-05	0.000263	CcSEcCtD
Imatinib—Diarrhoea—Glyburide—type 2 diabetes mellitus	4.4e-05	0.000263	CcSEcCtD
Imatinib—Dry mouth—Losartan—type 2 diabetes mellitus	4.37e-05	0.000262	CcSEcCtD
Imatinib—Anorexia—Irbesartan—type 2 diabetes mellitus	4.34e-05	0.00026	CcSEcCtD
Imatinib—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	4.33e-05	0.000259	CcSEcCtD
Imatinib—Paraesthesia—Metformin—type 2 diabetes mellitus	4.33e-05	0.000259	CcSEcCtD
Imatinib—Muscle spasms—Ramipril—type 2 diabetes mellitus	4.33e-05	0.000259	CcSEcCtD
Imatinib—Confusional state—Losartan—type 2 diabetes mellitus	4.32e-05	0.000259	CcSEcCtD
Imatinib—Feeling abnormal—Orlistat—type 2 diabetes mellitus	4.32e-05	0.000258	CcSEcCtD
Imatinib—Dyspnoea—Metformin—type 2 diabetes mellitus	4.3e-05	0.000258	CcSEcCtD
Imatinib—Somnolence—Metformin—type 2 diabetes mellitus	4.29e-05	0.000257	CcSEcCtD
Imatinib—Anaphylactic shock—Losartan—type 2 diabetes mellitus	4.29e-05	0.000257	CcSEcCtD
Imatinib—Oedema—Losartan—type 2 diabetes mellitus	4.29e-05	0.000257	CcSEcCtD
Imatinib—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	4.28e-05	0.000256	CcSEcCtD
Imatinib—Infection—Losartan—type 2 diabetes mellitus	4.26e-05	0.000255	CcSEcCtD
Imatinib—Hypotension—Irbesartan—type 2 diabetes mellitus	4.26e-05	0.000255	CcSEcCtD
Imatinib—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	4.25e-05	0.000254	CcSEcCtD
Imatinib—Dyspepsia—Metformin—type 2 diabetes mellitus	4.25e-05	0.000254	CcSEcCtD
Imatinib—Tremor—Ramipril—type 2 diabetes mellitus	4.22e-05	0.000253	CcSEcCtD
Imatinib—Shock—Losartan—type 2 diabetes mellitus	4.22e-05	0.000252	CcSEcCtD
Imatinib—Urticaria—Valsartan—type 2 diabetes mellitus	4.21e-05	0.000252	CcSEcCtD
Imatinib—Nervous system disorder—Losartan—type 2 diabetes mellitus	4.2e-05	0.000252	CcSEcCtD
Imatinib—Thrombocytopenia—Losartan—type 2 diabetes mellitus	4.2e-05	0.000251	CcSEcCtD
Imatinib—Decreased appetite—Metformin—type 2 diabetes mellitus	4.2e-05	0.000251	CcSEcCtD
Imatinib—Abdominal pain—Valsartan—type 2 diabetes mellitus	4.19e-05	0.000251	CcSEcCtD
Imatinib—Tachycardia—Losartan—type 2 diabetes mellitus	4.18e-05	0.00025	CcSEcCtD
Imatinib—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	4.18e-05	0.00025	CcSEcCtD
Imatinib—Nausea—Bromocriptine—type 2 diabetes mellitus	4.17e-05	0.00025	CcSEcCtD
Imatinib—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	4.17e-05	0.000249	CcSEcCtD
Imatinib—Fatigue—Metformin—type 2 diabetes mellitus	4.16e-05	0.000249	CcSEcCtD
Imatinib—Urticaria—Orlistat—type 2 diabetes mellitus	4.16e-05	0.000249	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	4.15e-05	0.000248	CcSEcCtD
Imatinib—Hyperhidrosis—Losartan—type 2 diabetes mellitus	4.14e-05	0.000248	CcSEcCtD
Imatinib—Body temperature increased—Orlistat—type 2 diabetes mellitus	4.14e-05	0.000248	CcSEcCtD
Imatinib—Abdominal pain—Orlistat—type 2 diabetes mellitus	4.14e-05	0.000248	CcSEcCtD
Imatinib—Asthenia—Gliclazide—type 2 diabetes mellitus	4.14e-05	0.000248	CcSEcCtD
Imatinib—Constipation—Metformin—type 2 diabetes mellitus	4.13e-05	0.000247	CcSEcCtD
Imatinib—Angioedema—Ramipril—type 2 diabetes mellitus	4.12e-05	0.000246	CcSEcCtD
Imatinib—Paraesthesia—Irbesartan—type 2 diabetes mellitus	4.09e-05	0.000245	CcSEcCtD
Imatinib—Anorexia—Losartan—type 2 diabetes mellitus	4.09e-05	0.000245	CcSEcCtD
Imatinib—Vomiting—Glyburide—type 2 diabetes mellitus	4.09e-05	0.000245	CcSEcCtD
Imatinib—Pruritus—Gliclazide—type 2 diabetes mellitus	4.08e-05	0.000244	CcSEcCtD
Imatinib—Malaise—Ramipril—type 2 diabetes mellitus	4.06e-05	0.000243	CcSEcCtD
Imatinib—Dyspnoea—Irbesartan—type 2 diabetes mellitus	4.06e-05	0.000243	CcSEcCtD
Imatinib—Rash—Glyburide—type 2 diabetes mellitus	4.05e-05	0.000243	CcSEcCtD
Imatinib—Somnolence—Irbesartan—type 2 diabetes mellitus	4.05e-05	0.000242	CcSEcCtD
Imatinib—Dermatitis—Glyburide—type 2 diabetes mellitus	4.05e-05	0.000242	CcSEcCtD
Imatinib—Vertigo—Ramipril—type 2 diabetes mellitus	4.05e-05	0.000242	CcSEcCtD
Imatinib—Syncope—Ramipril—type 2 diabetes mellitus	4.04e-05	0.000242	CcSEcCtD
Imatinib—Leukopenia—Ramipril—type 2 diabetes mellitus	4.03e-05	0.000241	CcSEcCtD
Imatinib—Headache—Glyburide—type 2 diabetes mellitus	4.03e-05	0.000241	CcSEcCtD
Imatinib—Dyspepsia—Irbesartan—type 2 diabetes mellitus	4.01e-05	0.00024	CcSEcCtD
Imatinib—Hypotension—Losartan—type 2 diabetes mellitus	4.01e-05	0.00024	CcSEcCtD
Imatinib—Palpitations—Ramipril—type 2 diabetes mellitus	3.98e-05	0.000238	CcSEcCtD
Imatinib—Feeling abnormal—Metformin—type 2 diabetes mellitus	3.98e-05	0.000238	CcSEcCtD
Imatinib—Decreased appetite—Irbesartan—type 2 diabetes mellitus	3.96e-05	0.000237	CcSEcCtD
Imatinib—Loss of consciousness—Ramipril—type 2 diabetes mellitus	3.96e-05	0.000237	CcSEcCtD
Imatinib—Diarrhoea—Gliclazide—type 2 diabetes mellitus	3.95e-05	0.000236	CcSEcCtD
Imatinib—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	3.95e-05	0.000236	CcSEcCtD
Imatinib—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	3.93e-05	0.000235	CcSEcCtD
Imatinib—Cough—Ramipril—type 2 diabetes mellitus	3.93e-05	0.000235	CcSEcCtD
Imatinib—Fatigue—Irbesartan—type 2 diabetes mellitus	3.93e-05	0.000235	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	3.91e-05	0.000234	CcSEcCtD
Imatinib—Hypersensitivity—Valsartan—type 2 diabetes mellitus	3.91e-05	0.000234	CcSEcCtD
Imatinib—Convulsion—Ramipril—type 2 diabetes mellitus	3.9e-05	0.000234	CcSEcCtD
Imatinib—Pain—Irbesartan—type 2 diabetes mellitus	3.9e-05	0.000233	CcSEcCtD
Imatinib—Constipation—Irbesartan—type 2 diabetes mellitus	3.9e-05	0.000233	CcSEcCtD
Imatinib—Insomnia—Losartan—type 2 diabetes mellitus	3.88e-05	0.000232	CcSEcCtD
Imatinib—Hypersensitivity—Orlistat—type 2 diabetes mellitus	3.86e-05	0.000231	CcSEcCtD
Imatinib—Paraesthesia—Losartan—type 2 diabetes mellitus	3.85e-05	0.00023	CcSEcCtD
Imatinib—Urticaria—Metformin—type 2 diabetes mellitus	3.83e-05	0.00023	CcSEcCtD
Imatinib—Arthralgia—Ramipril—type 2 diabetes mellitus	3.83e-05	0.00023	CcSEcCtD
Imatinib—Myalgia—Ramipril—type 2 diabetes mellitus	3.83e-05	0.00023	CcSEcCtD
Imatinib—Chest pain—Ramipril—type 2 diabetes mellitus	3.83e-05	0.00023	CcSEcCtD
Imatinib—Dyspnoea—Losartan—type 2 diabetes mellitus	3.82e-05	0.000229	CcSEcCtD
Imatinib—Anxiety—Ramipril—type 2 diabetes mellitus	3.82e-05	0.000229	CcSEcCtD
Imatinib—Nausea—Glyburide—type 2 diabetes mellitus	3.82e-05	0.000228	CcSEcCtD
Imatinib—Abdominal pain—Metformin—type 2 diabetes mellitus	3.82e-05	0.000228	CcSEcCtD
Imatinib—Dizziness—Gliclazide—type 2 diabetes mellitus	3.82e-05	0.000228	CcSEcCtD
Imatinib—Somnolence—Losartan—type 2 diabetes mellitus	3.81e-05	0.000228	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	3.81e-05	0.000228	CcSEcCtD
Imatinib—Asthenia—Valsartan—type 2 diabetes mellitus	3.8e-05	0.000228	CcSEcCtD
Imatinib—Discomfort—Ramipril—type 2 diabetes mellitus	3.79e-05	0.000227	CcSEcCtD
Imatinib—Dyspepsia—Losartan—type 2 diabetes mellitus	3.77e-05	0.000226	CcSEcCtD
Imatinib—Asthenia—Orlistat—type 2 diabetes mellitus	3.76e-05	0.000225	CcSEcCtD
Imatinib—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	3.75e-05	0.000225	CcSEcCtD
Imatinib—Pruritus—Valsartan—type 2 diabetes mellitus	3.75e-05	0.000224	CcSEcCtD
Imatinib—Dry mouth—Ramipril—type 2 diabetes mellitus	3.75e-05	0.000224	CcSEcCtD
Imatinib—Decreased appetite—Losartan—type 2 diabetes mellitus	3.73e-05	0.000223	CcSEcCtD
Imatinib—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	3.73e-05	0.000223	CcSEcCtD
Imatinib—Confusional state—Ramipril—type 2 diabetes mellitus	3.71e-05	0.000222	CcSEcCtD
Imatinib—Pruritus—Orlistat—type 2 diabetes mellitus	3.71e-05	0.000222	CcSEcCtD
Imatinib—Fatigue—Losartan—type 2 diabetes mellitus	3.7e-05	0.000221	CcSEcCtD
Imatinib—Oedema—Ramipril—type 2 diabetes mellitus	3.68e-05	0.00022	CcSEcCtD
Imatinib—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	3.68e-05	0.00022	CcSEcCtD
Imatinib—Vomiting—Gliclazide—type 2 diabetes mellitus	3.67e-05	0.00022	CcSEcCtD
Imatinib—Pain—Losartan—type 2 diabetes mellitus	3.67e-05	0.000219	CcSEcCtD
Imatinib—Constipation—Losartan—type 2 diabetes mellitus	3.67e-05	0.000219	CcSEcCtD
Imatinib—Rash—Gliclazide—type 2 diabetes mellitus	3.64e-05	0.000218	CcSEcCtD
Imatinib—Dermatitis—Gliclazide—type 2 diabetes mellitus	3.63e-05	0.000218	CcSEcCtD
Imatinib—Diarrhoea—Valsartan—type 2 diabetes mellitus	3.63e-05	0.000217	CcSEcCtD
Imatinib—Urticaria—Irbesartan—type 2 diabetes mellitus	3.62e-05	0.000217	CcSEcCtD
Imatinib—Shock—Ramipril—type 2 diabetes mellitus	3.62e-05	0.000216	CcSEcCtD
Imatinib—Headache—Gliclazide—type 2 diabetes mellitus	3.61e-05	0.000216	CcSEcCtD
Imatinib—Nervous system disorder—Ramipril—type 2 diabetes mellitus	3.6e-05	0.000216	CcSEcCtD
Imatinib—Abdominal pain—Irbesartan—type 2 diabetes mellitus	3.6e-05	0.000216	CcSEcCtD
Imatinib—Body temperature increased—Irbesartan—type 2 diabetes mellitus	3.6e-05	0.000216	CcSEcCtD
Imatinib—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	3.6e-05	0.000215	CcSEcCtD
Imatinib—Tachycardia—Ramipril—type 2 diabetes mellitus	3.59e-05	0.000215	CcSEcCtD
Imatinib—Diarrhoea—Orlistat—type 2 diabetes mellitus	3.58e-05	0.000215	CcSEcCtD
Imatinib—Skin disorder—Ramipril—type 2 diabetes mellitus	3.57e-05	0.000214	CcSEcCtD
Imatinib—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	3.55e-05	0.000213	CcSEcCtD
Imatinib—Feeling abnormal—Losartan—type 2 diabetes mellitus	3.53e-05	0.000211	CcSEcCtD
Imatinib—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	3.51e-05	0.00021	CcSEcCtD
Imatinib—Dizziness—Valsartan—type 2 diabetes mellitus	3.51e-05	0.00021	CcSEcCtD
Imatinib—Anorexia—Ramipril—type 2 diabetes mellitus	3.5e-05	0.00021	CcSEcCtD
Imatinib—Dizziness—Orlistat—type 2 diabetes mellitus	3.46e-05	0.000207	CcSEcCtD
Imatinib—Asthenia—Metformin—type 2 diabetes mellitus	3.46e-05	0.000207	CcSEcCtD
Imatinib—Hypotension—Ramipril—type 2 diabetes mellitus	3.43e-05	0.000206	CcSEcCtD
Imatinib—Nausea—Gliclazide—type 2 diabetes mellitus	3.43e-05	0.000205	CcSEcCtD
Imatinib—Pruritus—Metformin—type 2 diabetes mellitus	3.42e-05	0.000204	CcSEcCtD
Imatinib—Urticaria—Losartan—type 2 diabetes mellitus	3.41e-05	0.000204	CcSEcCtD
Imatinib—Abdominal pain—Losartan—type 2 diabetes mellitus	3.39e-05	0.000203	CcSEcCtD
Imatinib—Body temperature increased—Losartan—type 2 diabetes mellitus	3.39e-05	0.000203	CcSEcCtD
Imatinib—Vomiting—Valsartan—type 2 diabetes mellitus	3.37e-05	0.000202	CcSEcCtD
Imatinib—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	3.36e-05	0.000201	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	3.35e-05	0.0002	CcSEcCtD
Imatinib—Rash—Valsartan—type 2 diabetes mellitus	3.34e-05	0.0002	CcSEcCtD
Imatinib—Dermatitis—Valsartan—type 2 diabetes mellitus	3.34e-05	0.0002	CcSEcCtD
Imatinib—Vomiting—Orlistat—type 2 diabetes mellitus	3.33e-05	0.000199	CcSEcCtD
Imatinib—Insomnia—Ramipril—type 2 diabetes mellitus	3.32e-05	0.000199	CcSEcCtD
Imatinib—Headache—Valsartan—type 2 diabetes mellitus	3.32e-05	0.000199	CcSEcCtD
Imatinib—Diarrhoea—Metformin—type 2 diabetes mellitus	3.3e-05	0.000198	CcSEcCtD
Imatinib—Rash—Orlistat—type 2 diabetes mellitus	3.3e-05	0.000198	CcSEcCtD
Imatinib—Paraesthesia—Ramipril—type 2 diabetes mellitus	3.3e-05	0.000198	CcSEcCtD
Imatinib—Dermatitis—Orlistat—type 2 diabetes mellitus	3.3e-05	0.000198	CcSEcCtD
Imatinib—Headache—Orlistat—type 2 diabetes mellitus	3.28e-05	0.000196	CcSEcCtD
Imatinib—Dyspnoea—Ramipril—type 2 diabetes mellitus	3.28e-05	0.000196	CcSEcCtD
Imatinib—Asthenia—Irbesartan—type 2 diabetes mellitus	3.27e-05	0.000196	CcSEcCtD
Imatinib—Somnolence—Ramipril—type 2 diabetes mellitus	3.27e-05	0.000196	CcSEcCtD
Imatinib—Dyspepsia—Ramipril—type 2 diabetes mellitus	3.24e-05	0.000194	CcSEcCtD
Imatinib—Pruritus—Irbesartan—type 2 diabetes mellitus	3.22e-05	0.000193	CcSEcCtD
Imatinib—Decreased appetite—Ramipril—type 2 diabetes mellitus	3.2e-05	0.000191	CcSEcCtD
Imatinib—Dizziness—Metformin—type 2 diabetes mellitus	3.19e-05	0.000191	CcSEcCtD
Imatinib—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	3.17e-05	0.00019	CcSEcCtD
Imatinib—Fatigue—Ramipril—type 2 diabetes mellitus	3.17e-05	0.00019	CcSEcCtD
Imatinib—Hypersensitivity—Losartan—type 2 diabetes mellitus	3.16e-05	0.000189	CcSEcCtD
Imatinib—Nausea—Valsartan—type 2 diabetes mellitus	3.15e-05	0.000188	CcSEcCtD
Imatinib—Constipation—Ramipril—type 2 diabetes mellitus	3.14e-05	0.000188	CcSEcCtD
Imatinib—Diarrhoea—Irbesartan—type 2 diabetes mellitus	3.12e-05	0.000187	CcSEcCtD
Imatinib—Nausea—Orlistat—type 2 diabetes mellitus	3.11e-05	0.000186	CcSEcCtD
Imatinib—Asthenia—Losartan—type 2 diabetes mellitus	3.08e-05	0.000184	CcSEcCtD
Imatinib—Vomiting—Metformin—type 2 diabetes mellitus	3.07e-05	0.000184	CcSEcCtD
Imatinib—Rash—Metformin—type 2 diabetes mellitus	3.04e-05	0.000182	CcSEcCtD
Imatinib—Dermatitis—Metformin—type 2 diabetes mellitus	3.04e-05	0.000182	CcSEcCtD
Imatinib—Pruritus—Losartan—type 2 diabetes mellitus	3.03e-05	0.000182	CcSEcCtD
Imatinib—Feeling abnormal—Ramipril—type 2 diabetes mellitus	3.03e-05	0.000181	CcSEcCtD
Imatinib—Headache—Metformin—type 2 diabetes mellitus	3.02e-05	0.000181	CcSEcCtD
Imatinib—Dizziness—Irbesartan—type 2 diabetes mellitus	3.01e-05	0.00018	CcSEcCtD
Imatinib—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	3.01e-05	0.00018	CcSEcCtD
Imatinib—Diarrhoea—Losartan—type 2 diabetes mellitus	2.93e-05	0.000176	CcSEcCtD
Imatinib—Urticaria—Ramipril—type 2 diabetes mellitus	2.92e-05	0.000175	CcSEcCtD
Imatinib—Abdominal pain—Ramipril—type 2 diabetes mellitus	2.91e-05	0.000174	CcSEcCtD
Imatinib—Body temperature increased—Ramipril—type 2 diabetes mellitus	2.91e-05	0.000174	CcSEcCtD
Imatinib—Vomiting—Irbesartan—type 2 diabetes mellitus	2.9e-05	0.000173	CcSEcCtD
Imatinib—Rash—Irbesartan—type 2 diabetes mellitus	2.87e-05	0.000172	CcSEcCtD
Imatinib—Dermatitis—Irbesartan—type 2 diabetes mellitus	2.87e-05	0.000172	CcSEcCtD
Imatinib—Nausea—Metformin—type 2 diabetes mellitus	2.87e-05	0.000172	CcSEcCtD
Imatinib—Headache—Irbesartan—type 2 diabetes mellitus	2.85e-05	0.000171	CcSEcCtD
Imatinib—Dizziness—Losartan—type 2 diabetes mellitus	2.83e-05	0.00017	CcSEcCtD
Imatinib—Vomiting—Losartan—type 2 diabetes mellitus	2.73e-05	0.000163	CcSEcCtD
Imatinib—Hypersensitivity—Ramipril—type 2 diabetes mellitus	2.71e-05	0.000162	CcSEcCtD
Imatinib—Nausea—Irbesartan—type 2 diabetes mellitus	2.71e-05	0.000162	CcSEcCtD
Imatinib—Rash—Losartan—type 2 diabetes mellitus	2.7e-05	0.000162	CcSEcCtD
Imatinib—Dermatitis—Losartan—type 2 diabetes mellitus	2.7e-05	0.000162	CcSEcCtD
Imatinib—Headache—Losartan—type 2 diabetes mellitus	2.69e-05	0.000161	CcSEcCtD
Imatinib—Asthenia—Ramipril—type 2 diabetes mellitus	2.64e-05	0.000158	CcSEcCtD
Imatinib—Pruritus—Ramipril—type 2 diabetes mellitus	2.6e-05	0.000156	CcSEcCtD
Imatinib—Nausea—Losartan—type 2 diabetes mellitus	2.55e-05	0.000152	CcSEcCtD
Imatinib—Diarrhoea—Ramipril—type 2 diabetes mellitus	2.52e-05	0.000151	CcSEcCtD
Imatinib—Dizziness—Ramipril—type 2 diabetes mellitus	2.43e-05	0.000146	CcSEcCtD
Imatinib—Vomiting—Ramipril—type 2 diabetes mellitus	2.34e-05	0.00014	CcSEcCtD
Imatinib—Rash—Ramipril—type 2 diabetes mellitus	2.32e-05	0.000139	CcSEcCtD
Imatinib—Dermatitis—Ramipril—type 2 diabetes mellitus	2.32e-05	0.000139	CcSEcCtD
Imatinib—Headache—Ramipril—type 2 diabetes mellitus	2.3e-05	0.000138	CcSEcCtD
Imatinib—Nausea—Ramipril—type 2 diabetes mellitus	2.18e-05	0.000131	CcSEcCtD
Imatinib—SLC22A1—Metabolism—NOS3—type 2 diabetes mellitus	1.45e-06	1.39e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PPP2CA—type 2 diabetes mellitus	1.45e-06	1.39e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL6—type 2 diabetes mellitus	1.45e-06	1.39e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTGS2—type 2 diabetes mellitus	1.44e-06	1.38e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—SLC2A1—type 2 diabetes mellitus	1.44e-06	1.38e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.44e-06	1.38e-05	CbGpPWpGaD
Imatinib—LCK—Disease—SRC—type 2 diabetes mellitus	1.43e-06	1.37e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	1.43e-06	1.37e-05	CbGpPWpGaD
Imatinib—CA9—Metabolism—AKT1—type 2 diabetes mellitus	1.43e-06	1.37e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.43e-06	1.37e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTGS2—type 2 diabetes mellitus	1.43e-06	1.37e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTGS2—type 2 diabetes mellitus	1.42e-06	1.36e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.42e-06	1.36e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	1.42e-06	1.36e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GSTM1—type 2 diabetes mellitus	1.41e-06	1.35e-05	CbGpPWpGaD
Imatinib—KIT—Disease—IL6—type 2 diabetes mellitus	1.41e-06	1.35e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—AKT1—type 2 diabetes mellitus	1.41e-06	1.35e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	1.4e-06	1.34e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	1.4e-06	1.34e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	1.4e-06	1.34e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.4e-06	1.34e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP3A4—type 2 diabetes mellitus	1.4e-06	1.34e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	1.4e-06	1.34e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	1.39e-06	1.34e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—MTHFR—type 2 diabetes mellitus	1.39e-06	1.33e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.39e-06	1.33e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GNB3—type 2 diabetes mellitus	1.39e-06	1.33e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SRC—type 2 diabetes mellitus	1.39e-06	1.33e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—LPL—type 2 diabetes mellitus	1.39e-06	1.33e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—HMOX1—type 2 diabetes mellitus	1.38e-06	1.33e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTGS2—type 2 diabetes mellitus	1.38e-06	1.32e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	1.38e-06	1.32e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GCG—type 2 diabetes mellitus	1.38e-06	1.32e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—SLC2A4—type 2 diabetes mellitus	1.38e-06	1.32e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	1.38e-06	1.32e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	1.38e-06	1.32e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	1.37e-06	1.31e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	1.37e-06	1.31e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	1.37e-06	1.31e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PPARA—type 2 diabetes mellitus	1.37e-06	1.31e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CAT—type 2 diabetes mellitus	1.36e-06	1.31e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—EGFR—type 2 diabetes mellitus	1.36e-06	1.3e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	1.36e-06	1.3e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ADCY5—type 2 diabetes mellitus	1.36e-06	1.3e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.36e-06	1.3e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.36e-06	1.3e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.36e-06	1.3e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	1.35e-06	1.3e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GPX1—type 2 diabetes mellitus	1.35e-06	1.3e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.35e-06	1.3e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.35e-06	1.29e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.34e-06	1.29e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	1.34e-06	1.28e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—IL6—type 2 diabetes mellitus	1.34e-06	1.28e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—AKT1—type 2 diabetes mellitus	1.34e-06	1.28e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	1.33e-06	1.28e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTGS2—type 2 diabetes mellitus	1.33e-06	1.27e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	1.33e-06	1.27e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—APOB—type 2 diabetes mellitus	1.33e-06	1.27e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—AGT—type 2 diabetes mellitus	1.32e-06	1.27e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	1.32e-06	1.27e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	1.32e-06	1.26e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CD36—type 2 diabetes mellitus	1.32e-06	1.26e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.31e-06	1.26e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PPARG—type 2 diabetes mellitus	1.31e-06	1.26e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL6—type 2 diabetes mellitus	1.3e-06	1.25e-05	CbGpPWpGaD
Imatinib—KIT—Disease—AKT1—type 2 diabetes mellitus	1.3e-06	1.25e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PPP2CA—type 2 diabetes mellitus	1.3e-06	1.25e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CALM1—type 2 diabetes mellitus	1.3e-06	1.25e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	1.3e-06	1.25e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—APOE—type 2 diabetes mellitus	1.3e-06	1.24e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTM1—type 2 diabetes mellitus	1.29e-06	1.23e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	1.29e-06	1.23e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.29e-06	1.23e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—INS—type 2 diabetes mellitus	1.29e-06	1.23e-05	CbGpPWpGaD
Imatinib—LCK—Disease—TGFB1—type 2 diabetes mellitus	1.28e-06	1.23e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—APOA1—type 2 diabetes mellitus	1.28e-06	1.23e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RELA—type 2 diabetes mellitus	1.28e-06	1.22e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	1.28e-06	1.22e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.27e-06	1.22e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL6—type 2 diabetes mellitus	1.27e-06	1.22e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—LPL—type 2 diabetes mellitus	1.27e-06	1.21e-05	CbGpPWpGaD
Imatinib—LCK—Disease—EGFR—type 2 diabetes mellitus	1.26e-06	1.2e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SRC—type 2 diabetes mellitus	1.25e-06	1.2e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	1.25e-06	1.2e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—MTHFR—type 2 diabetes mellitus	1.25e-06	1.2e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	1.25e-06	1.19e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.24e-06	1.19e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.24e-06	1.19e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ADCY5—type 2 diabetes mellitus	1.24e-06	1.19e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GPX1—type 2 diabetes mellitus	1.23e-06	1.18e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—AKT1—type 2 diabetes mellitus	1.23e-06	1.18e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	1.23e-06	1.17e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	1.23e-06	1.17e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	1.23e-06	1.17e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PPARA—type 2 diabetes mellitus	1.23e-06	1.17e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	1.22e-06	1.17e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.22e-06	1.17e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.22e-06	1.17e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	1.21e-06	1.16e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IL6—type 2 diabetes mellitus	1.2e-06	1.15e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	1.2e-06	1.15e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—AKT1—type 2 diabetes mellitus	1.2e-06	1.15e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CD36—type 2 diabetes mellitus	1.2e-06	1.15e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	1.2e-06	1.15e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	1.2e-06	1.15e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	1.19e-06	1.14e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.19e-06	1.14e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	1.19e-06	1.14e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PPP2CA—type 2 diabetes mellitus	1.19e-06	1.14e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AGT—type 2 diabetes mellitus	1.19e-06	1.14e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	1.18e-06	1.13e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ALB—type 2 diabetes mellitus	1.18e-06	1.13e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—AKT1—type 2 diabetes mellitus	1.17e-06	1.12e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	1.17e-06	1.12e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CALM1—type 2 diabetes mellitus	1.17e-06	1.12e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	1.17e-06	1.12e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—APOE—type 2 diabetes mellitus	1.16e-06	1.11e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	1.16e-06	1.11e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.15e-06	1.1e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—APOA1—type 2 diabetes mellitus	1.15e-06	1.1e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	1.15e-06	1.1e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	1.14e-06	1.09e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—MTHFR—type 2 diabetes mellitus	1.14e-06	1.09e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	1.14e-06	1.09e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	1.13e-06	1.08e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PPARG—type 2 diabetes mellitus	1.13e-06	1.08e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	1.13e-06	1.08e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3R1—type 2 diabetes mellitus	1.13e-06	1.08e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—NOS3—type 2 diabetes mellitus	1.13e-06	1.08e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	1.12e-06	1.07e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	1.12e-06	1.07e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.12e-06	1.07e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PPARA—type 2 diabetes mellitus	1.12e-06	1.07e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—AKT1—type 2 diabetes mellitus	1.11e-06	1.06e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	1.11e-06	1.06e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	1.11e-06	1.06e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—INS—type 2 diabetes mellitus	1.11e-06	1.06e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	1.1e-06	1.06e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—AKT1—type 2 diabetes mellitus	1.1e-06	1.05e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.1e-06	1.05e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	1.09e-06	1.05e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.09e-06	1.04e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AGT—type 2 diabetes mellitus	1.08e-06	1.04e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	1.08e-06	1.04e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.08e-06	1.03e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	1.07e-06	1.03e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	1.07e-06	1.02e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CALM1—type 2 diabetes mellitus	1.06e-06	1.02e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	1.06e-06	1.02e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	1.06e-06	1.02e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—APOE—type 2 diabetes mellitus	1.06e-06	1.02e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	1.06e-06	1.01e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	1.06e-06	1.01e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	1.05e-06	1.01e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—APOA1—type 2 diabetes mellitus	1.05e-06	1e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL6—type 2 diabetes mellitus	1.05e-06	1e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTGS2—type 2 diabetes mellitus	1.03e-06	9.87e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	1.03e-06	9.84e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	1.01e-06	9.72e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PPARG—type 2 diabetes mellitus	1.01e-06	9.7e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SRC—type 2 diabetes mellitus	1e-06	9.62e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—INS—type 2 diabetes mellitus	9.94e-07	9.52e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	9.89e-07	9.47e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL6—type 2 diabetes mellitus	9.89e-07	9.47e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.78e-07	9.37e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	9.73e-07	9.32e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3R1—type 2 diabetes mellitus	9.71e-07	9.3e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—NOS3—type 2 diabetes mellitus	9.71e-07	9.3e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—INS—type 2 diabetes mellitus	9.7e-07	9.29e-06	CbGpPWpGaD
Imatinib—LCK—Disease—IL6—type 2 diabetes mellitus	9.66e-07	9.25e-06	CbGpPWpGaD
Imatinib—LCK—Immune System—AKT1—type 2 diabetes mellitus	9.65e-07	9.25e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	9.55e-07	9.15e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL6—type 2 diabetes mellitus	9.36e-07	8.96e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	9.32e-07	8.93e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	9.25e-07	8.86e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PPARG—type 2 diabetes mellitus	9.24e-07	8.85e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	9.17e-07	8.78e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	9.17e-07	8.78e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	9.14e-07	8.75e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	9.12e-07	8.74e-06	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.12e-07	8.74e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ALB—type 2 diabetes mellitus	9.11e-07	8.73e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	9.09e-07	8.71e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	9.06e-07	8.68e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—INS—type 2 diabetes mellitus	9.06e-07	8.68e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	9e-07	8.62e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.98e-07	8.6e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	8.96e-07	8.58e-06	CbGpPWpGaD
Imatinib—LCK—Disease—AKT1—type 2 diabetes mellitus	8.91e-07	8.54e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	8.89e-07	8.52e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTGS2—type 2 diabetes mellitus	8.88e-07	8.5e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.8e-07	8.43e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	8.74e-07	8.37e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3R1—type 2 diabetes mellitus	8.71e-07	8.35e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—NOS3—type 2 diabetes mellitus	8.71e-07	8.35e-06	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.63e-07	8.27e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	8.51e-07	8.15e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	8.51e-07	8.15e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	8.5e-07	8.14e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL6—type 2 diabetes mellitus	8.43e-07	8.08e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	8.38e-07	8.03e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	8.34e-07	7.99e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ALB—type 2 diabetes mellitus	8.31e-07	7.96e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	8.17e-07	7.82e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	8.14e-07	7.8e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	8.01e-07	7.68e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	8.01e-07	7.68e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTGS2—type 2 diabetes mellitus	7.97e-07	7.63e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3R1—type 2 diabetes mellitus	7.95e-07	7.61e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—NOS3—type 2 diabetes mellitus	7.95e-07	7.61e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	7.93e-07	7.59e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	7.89e-07	7.56e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	7.83e-07	7.5e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	7.78e-07	7.45e-06	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.78e-07	7.45e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	7.74e-07	7.42e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	7.51e-07	7.2e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	7.37e-07	7.06e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	7.33e-07	7.02e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTGS2—type 2 diabetes mellitus	7.27e-07	6.96e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—AKT1—type 2 diabetes mellitus	7.23e-07	6.93e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—AKT1—type 2 diabetes mellitus	7.17e-07	6.87e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—AKT1—type 2 diabetes mellitus	7.16e-07	6.86e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	7.14e-07	6.84e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	7.1e-07	6.8e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	7.02e-07	6.72e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	6.99e-07	6.7e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—AKT1—type 2 diabetes mellitus	6.95e-07	6.65e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	6.91e-07	6.62e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	6.79e-07	6.5e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	6.79e-07	6.5e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6—type 2 diabetes mellitus	6.77e-07	6.48e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—AKT1—type 2 diabetes mellitus	6.67e-07	6.39e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.24e-07	5.98e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	6.21e-07	5.95e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	6.09e-07	5.84e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	5.98e-07	5.72e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	5.48e-07	5.25e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	5.24e-07	5.02e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	5.24e-07	5.02e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AKT1—type 2 diabetes mellitus	5.18e-07	4.96e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	4.79e-07	4.59e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—AKT1—type 2 diabetes mellitus	4.46e-07	4.27e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AKT1—type 2 diabetes mellitus	4.01e-07	3.84e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	3.91e-07	3.74e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	3.68e-07	3.53e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AKT1—type 2 diabetes mellitus	3.65e-07	3.5e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	3.12e-07	2.99e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	2.41e-07	2.31e-06	CbGpPWpGaD
